+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Peptide Therapeutics Market Research Report by Technology, API Type, Drug Class, Application, End-user, and State - United States Forecast to 2026 - Cumulative Impact of COVID-19

  • ID: 5124578
  • Report
  • October 2021
  • Region: United States
  • 186 Pages
  • 360iResearch™
UP TO OFF
until Jan 01st 2022
United States Peptide Therapeutics Market is Projected to Reach USD 8,363.80 Million by 2026, Registering a CAGR of 9.99%

FEATURED COMPANIES

  • AmbioPharm Inc.
  • AstraZeneca PLC
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Merck & Co. Inc.
  • Novo Nordisk A/S
The United States Peptide Therapeutics Market size was estimated at USD 4,721.66 million in 2020, is expected to reach USD 5,102.08 million in 2021, and projected to grow at a CAGR of 9.99% reaching USD 8,363.80 million by 2026.



Market Statistics


The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage


This research report categorizes the Peptide Therapeutics to forecast the revenues and analyze the trends in each of the following sub-markets:

  • Based on Technology, the market was studied across Hybrid Phase, Liquid Phase, and Solid Phase.
  • Based on API Type, the market was studied across CMO and In-house.
  • Based on Drug Class, the market was studied across Calcitonins, Glucagon & Analogs, Insulins, Luteinizing Hormone-Releasing Hormone, Somatostatins, and Vasopressin.
  • Based on Application, the market was studied across Anti-infective, Cancer, Cardio Vascular Disease Respiratory, Central Nervous System, Dermatology, Gastrointestinal, Metabolic, and Renal.
  • Based on End-user, the market was studied across Hospitals, Pharmaceutical Industries, and Research Laboratories.
  • Based on State, the market was studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas.

Cumulative Impact of COVID-19


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. The analyst's ongoing research amplifies their research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix


The FPNV Positioning Matrix evaluates and categorizes the vendors in the Peptide Therapeutics Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario


The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles


The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the United States Peptide Therapeutics Market, including AmbioPharm Inc., Amgen Inc., AstraZeneca PLC, Bachem Holding AG, Bristol-Myers Squibb Company, CordenPharma International, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Hemmo Pharmaceuticals Pvt Ltd., Ipsen S.A., Merck & Co., Inc., Novartis International AG, Novo Nordisk A/S, Pfizer Inc., PolyPeptide Group, Sanofi S.A., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Zealand Pharma A/S.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the United States Peptide Therapeutics Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the United States Peptide Therapeutics Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the United States Peptide Therapeutics Market?
4. What is the competitive strategic window for opportunities in the United States Peptide Therapeutics Market?
5. What are the technology trends and regulatory frameworks in the United States Peptide Therapeutics Market?
6. What is the market share of the leading vendors in the United States Peptide Therapeutics Market?
7. What modes and strategic moves are considered suitable for entering the United States Peptide Therapeutics Market?
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AmbioPharm Inc.
  • AstraZeneca PLC
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Merck & Co. Inc.
  • Novo Nordisk A/S
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
3.1. Introduction

4. Market Overview
4.1. Introduction
4.2. Cumulative Impact of COVID-19

5. Market Dynamics
5.1. Introduction
5.2. Drivers
5.3. Restraints
5.4. Opportunities
5.5. Challenges

6. Peptide Therapeutics Market, by Technology
6.1. Introduction
6.2. Hybrid Phase
6.3. Liquid Phase
6.4. Solid Phase

7. Peptide Therapeutics Market, by API Type
7.1. Introduction
7.2. CMO
7.3. In-house

8. Peptide Therapeutics Market, by Drug Class
8.1. Introduction
8.2. Calcitonins
8.3. Glucagon & Analogs
8.4. Insulins
8.5. Luteinizing Hormone-Releasing Hormone
8.6. Somatostatins
8.7. Vasopressin

9. Peptide Therapeutics Market, by Application
9.1. Introduction
9.2. Anti-infective
9.3. Cancer
9.4. Cardio Vascular Disease Respiratory
9.5. Central Nervous System
9.6. Dermatology
9.7. Gastrointestinal
9.8. Metabolic
9.9. Renal

10. Peptide Therapeutics Market, by End-user
10.1. Introduction
10.2. Hospitals
10.3. Pharmaceutical Industries
10.4. Research Laboratories

11. California Peptide Therapeutics Market

12. Florida Peptide Therapeutics Market

13. Illinois Peptide Therapeutics Market

14. New York Peptide Therapeutics Market

15. Ohio Peptide Therapeutics Market

16. Pennsylvania Peptide Therapeutics Market

17. Texas Peptide Therapeutics Market

18. Competitive Landscape
18.1. FPNV Positioning Matrix
18.1.1. Quadrants
18.1.2. Business Strategy
18.1.3. Product Satisfaction
18.2. Market Ranking Analysis
18.3. Market Share Analysis, by Key Player
18.4. Competitive Scenario
18.4.1. Merger & Acquisition
18.4.2. Agreement, Collaboration, & Partnership
18.4.3. New Product Launch & Enhancement
18.4.4. Investment & Funding
18.4.5. Award, Recognition, & Expansion

19. Company Usability Profiles
19.1. AmbioPharm Inc.
19.2. Amgen Inc.
19.3. AstraZeneca PLC
19.4. Bachem Holding AG
19.5. Bristol-Myers Squibb Company
19.6. CordenPharma International
19.7. Eli Lilly and Company
19.8. F. Hoffmann-La Roche AG
19.9. GlaxoSmithKline PLC
19.10. Hemmo Pharmaceuticals Pvt Ltd.
19.11. Ipsen S.A.
19.12. Merck & Co., Inc.
19.13. Novartis International AG
19.14. Novo Nordisk A/S
19.15. Pfizer Inc.
19.16. PolyPeptide Group
19.17. Sanofi S.A.
19.18. Takeda Pharmaceutical Company Limited
19.19. Teva Pharmaceutical Industries Ltd.
19.20. Zealand Pharma A/S

20. Appendix
20.1. Discussion Guide
20.2. License & Pricing

List of Figures
Figure 1. United States Peptide Therapeutics Market Size, 2020 vs 2026 (USD Million)
Figure 2. United States Peptide Therapeutics Market Size, 2018-2026 (USD Million)
Figure 3. United States Peptide Therapeutics Market: Market Dynamics
Figure 4. United States Peptide Therapeutics Market Size, by Technology, 2020 vs 2026 (%)
Figure 5. United States Peptide Therapeutics Market Size, by Technology, 2020 vs 2026 (USD Million)
Figure 6. Competitive Strategic Window for United States Peptide Therapeutics Market Size, by Technology, 2026
Figure 7. United States Peptide Therapeutics Market Size, by Hybrid Phase, 2018-2026 (USD Million)
Figure 8. United States Peptide Therapeutics Market Size, by Hybrid Phase, by State, 2020 vs 2026 (USD Million)
Figure 9. United States Peptide Therapeutics Market Size, by Liquid Phase, 2018-2026 (USD Million)
Figure 10. United States Peptide Therapeutics Market Size, by Liquid Phase, by State, 2020 vs 2026 (USD Million)
Figure 11. United States Peptide Therapeutics Market Size, by Solid Phase, 2018-2026 (USD Million)
Figure 12. United States Peptide Therapeutics Market Size, by Solid Phase, by State, 2020 vs 2026 (USD Million)
Figure 13. United States Peptide Therapeutics Market Size, by Api Type, 2020 vs 2026 (%)
Figure 14. United States Peptide Therapeutics Market Size, by Api Type, 2020 vs 2026 (USD Million)
Figure 15. Competitive Strategic Window for United States Peptide Therapeutics Market Size, by Api Type, 2026
Figure 16. United States Peptide Therapeutics Market Size, by Cmo, 2018-2026 (USD Million)
Figure 17. United States Peptide Therapeutics Market Size, by Cmo, by State, 2020 vs 2026 (USD Million)
Figure 18. United States Peptide Therapeutics Market Size, by In-House, 2018-2026 (USD Million)
Figure 19. United States Peptide Therapeutics Market Size, by In-House, by State, 2020 vs 2026 (USD Million)
Figure 20. United States Peptide Therapeutics Market Size, by Drug Class, 2020 vs 2026 (%)
Figure 21. United States Peptide Therapeutics Market Size, by Drug Class, 2020 vs 2026 (USD Million)
Figure 22. Competitive Strategic Window for United States Peptide Therapeutics Market Size, by Drug Class, 2026
Figure 23. United States Peptide Therapeutics Market Size, by Calcitonins, 2018-2026 (USD Million)
Figure 24. United States Peptide Therapeutics Market Size, by Calcitonins, by State, 2020 vs 2026 (USD Million)
Figure 25. United States Peptide Therapeutics Market Size, by Glucagon & Analogs, 2018-2026 (USD Million)
Figure 26. United States Peptide Therapeutics Market Size, by Glucagon & Analogs, by State, 2020 vs 2026 (USD Million)
Figure 27. United States Peptide Therapeutics Market Size, by Insulins, 2018-2026 (USD Million)
Figure 28. United States Peptide Therapeutics Market Size, by Insulins, by State, 2020 vs 2026 (USD Million)
Figure 29. United States Peptide Therapeutics Market Size, by Luteinizing Hormone-Releasing Hormone, 2018-2026 (USD Million)
Figure 30. United States Peptide Therapeutics Market Size, by Luteinizing Hormone-Releasing Hormone, by State, 2020 vs 2026 (USD Million)
Figure 31. United States Peptide Therapeutics Market Size, by Somatostatins, 2018-2026 (USD Million)
Figure 32. United States Peptide Therapeutics Market Size, by Somatostatins, by State, 2020 vs 2026 (USD Million)
Figure 33. United States Peptide Therapeutics Market Size, by Vasopressin, 2018-2026 (USD Million)
Figure 34. United States Peptide Therapeutics Market Size, by Vasopressin, by State, 2020 vs 2026 (USD Million)
Figure 35. United States Peptide Therapeutics Market Size, by Application, 2020 vs 2026 (%)
Figure 36. United States Peptide Therapeutics Market Size, by Application, 2020 vs 2026 (USD Million)
Figure 37. Competitive Strategic Window for United States Peptide Therapeutics Market Size, by Application, 2026
Figure 38. United States Peptide Therapeutics Market Size, by Anti-Infective, 2018-2026 (USD Million)
Figure 39. United States Peptide Therapeutics Market Size, by Anti-Infective, by State, 2020 vs 2026 (USD Million)
Figure 40. United States Peptide Therapeutics Market Size, by Cancer, 2018-2026 (USD Million)
Figure 41. United States Peptide Therapeutics Market Size, by Cancer, by State, 2020 vs 2026 (USD Million)
Figure 42. United States Peptide Therapeutics Market Size, by Cardio Vascular Disease Respiratory, 2018-2026 (USD Million)
Figure 43. United States Peptide Therapeutics Market Size, by Cardio Vascular Disease Respiratory, by State, 2020 vs 2026 (USD Million)
Figure 44. United States Peptide Therapeutics Market Size, by Central Nervous System, 2018-2026 (USD Million)
Figure 45. United States Peptide Therapeutics Market Size, by Central Nervous System, by State, 2020 vs 2026 (USD Million)
Figure 46. United States Peptide Therapeutics Market Size, by Dermatology, 2018-2026 (USD Million)
Figure 47. United States Peptide Therapeutics Market Size, by Dermatology, by State, 2020 vs 2026 (USD Million)
Figure 48. United States Peptide Therapeutics Market Size, by Gastrointestinal, 2018-2026 (USD Million)
Figure 49. United States Peptide Therapeutics Market Size, by Gastrointestinal, by State, 2020 vs 2026 (USD Million)
Figure 50. United States Peptide Therapeutics Market Size, by Metabolic, 2018-2026 (USD Million)
Figure 51. United States Peptide Therapeutics Market Size, by Metabolic, by State, 2020 vs 2026 (USD Million)
Figure 52. United States Peptide Therapeutics Market Size, by Renal, 2018-2026 (USD Million)
Figure 53. United States Peptide Therapeutics Market Size, by Renal, by State, 2020 vs 2026 (USD Million)
Figure 54. United States Peptide Therapeutics Market Size, by End-user, 2020 vs 2026 (%)
Figure 55. United States Peptide Therapeutics Market Size, by End-user, 2020 vs 2026 (USD Million)
Figure 56. Competitive Strategic Window for United States Peptide Therapeutics Market Size, by End-user, 2026
Figure 57. United States Peptide Therapeutics Market Size, by Hospitals, 2018-2026 (USD Million)
Figure 58. United States Peptide Therapeutics Market Size, by Hospitals, by State, 2020 vs 2026 (USD Million)
Figure 59. United States Peptide Therapeutics Market Size, by Pharmaceutical Industries, 2018-2026 (USD Million)
Figure 60. United States Peptide Therapeutics Market Size, by Pharmaceutical Industries, by State, 2020 vs 2026 (USD Million)
Figure 61. United States Peptide Therapeutics Market Size, by Research Laboratories, 2018-2026 (USD Million)
Figure 62. United States Peptide Therapeutics Market Size, by Research Laboratories, by State, 2020 vs 2026 (USD Million)
Figure 63. United States Peptide Therapeutics Market: FPNV Positioning Matrix
Figure 64. United States Peptide Therapeutics Market: Share, by Key Player, 2020
Figure 65. Competitive Scenario Analysis in United States Peptide Therapeutics Market, by Type

List of Tables
Table 1. United States Peptide Therapeutics Market: Market Segmentation & Coverage
Table 2. United States Dollar Exchange Rate, 2016–2020
Table 3. United States Peptide Therapeutics Market Size, 2018-2026 (USD Million)
Table 4. United States Peptide Therapeutics Market Size, by Technology, 2018-2026 (USD Million)
Table 5. United States Peptide Therapeutics Market Size, by Hybrid Phase, by State, 2018-2026 (USD Million)
Table 6. United States Peptide Therapeutics Market Size, by Liquid Phase, by State, 2018-2026 (USD Million)
Table 7. United States Peptide Therapeutics Market Size, by Solid Phase, by State, 2018-2026 (USD Million)
Table 8. United States Peptide Therapeutics Market Size, by Api Type, 2018-2026 (USD Million)
Table 9. United States Peptide Therapeutics Market Size, by Cmo, by State, 2018-2026 (USD Million)
Table 10. United States Peptide Therapeutics Market Size, by In-House, by State, 2018-2026 (USD Million)
Table 11. United States Peptide Therapeutics Market Size, by Drug Class, 2018-2026 (USD Million)
Table 12. United States Peptide Therapeutics Market Size, by Calcitonins, by State, 2018-2026 (USD Million)
Table 13. United States Peptide Therapeutics Market Size, by Glucagon & Analogs, by State, 2018-2026 (USD Million)
Table 14. United States Peptide Therapeutics Market Size, by Insulins, by State, 2018-2026 (USD Million)
Table 15. United States Peptide Therapeutics Market Size, by Luteinizing Hormone-Releasing Hormone, by State, 2018-2026 (USD Million)
Table 16. United States Peptide Therapeutics Market Size, by Somatostatins, by State, 2018-2026 (USD Million)
Table 17. United States Peptide Therapeutics Market Size, by Vasopressin, by State, 2018-2026 (USD Million)
Table 18. United States Peptide Therapeutics Market Size, by Application, 2018-2026 (USD Million)
Table 19. United States Peptide Therapeutics Market Size, by Anti-Infective, by State, 2018-2026 (USD Million)
Table 20. United States Peptide Therapeutics Market Size, by Cancer, by State, 2018-2026 (USD Million)
Table 21. United States Peptide Therapeutics Market Size, by Cardio Vascular Disease Respiratory, by State, 2018-2026 (USD Million)
Table 22. United States Peptide Therapeutics Market Size, by Central Nervous System, by State, 2018-2026 (USD Million)
Table 23. United States Peptide Therapeutics Market Size, by Dermatology, by State, 2018-2026 (USD Million)
Table 24. United States Peptide Therapeutics Market Size, by Gastrointestinal, by State, 2018-2026 (USD Million)
Table 25. United States Peptide Therapeutics Market Size, by Metabolic, by State, 2018-2026 (USD Million)
Table 26. United States Peptide Therapeutics Market Size, by Renal, by State, 2018-2026 (USD Million)
Table 27. United States Peptide Therapeutics Market Size, by End-user, 2018-2026 (USD Million)
Table 28. United States Peptide Therapeutics Market Size, by Hospitals, by State, 2018-2026 (USD Million)
Table 29. United States Peptide Therapeutics Market Size, by Pharmaceutical Industries, by State, 2018-2026 (USD Million)
Table 30. United States Peptide Therapeutics Market Size, by Research Laboratories, by State, 2018-2026 (USD Million)
Table 31. United States Peptide Therapeutics Market: Scores
Table 32. United States Peptide Therapeutics Market: Business Strategy
Table 33. United States Peptide Therapeutics Market: Product Satisfaction
Table 34. United States Peptide Therapeutics Market: Ranking
Table 35. United States Peptide Therapeutics Market: Share, by Key Player, 2020
Table 36. United States Peptide Therapeutics Market: Merger & Acquisition
Table 37. United States Peptide Therapeutics Market: Agreement, Collaboration & Partnership
Table 38. United States Peptide Therapeutics Market: New Product Launch & Enhancement
Table 39. United States Peptide Therapeutics Market: Investment & Funding
Table 40. United States Peptide Therapeutics Market: Award, Recognition & Expansion
Table 41. United States Peptide Therapeutics Market: License & Pricing
Note: Product cover images may vary from those shown
  • AmbioPharm Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bachem Holding AG
  • Bristol-Myers Squibb Company
  • CordenPharma International
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Hemmo Pharmaceuticals Pvt Ltd.
  • Ipsen S.A.
  • Merck & Co. Inc.
  • Novartis International AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • PolyPeptide Group
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Zealand Pharma A/S
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll